VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASCO 2015 | Results for the follow-up of the RESPONSE study

Jean-Jacques Kiladjian • 2 Jun 2015
ASCO 2015
Myeloproliferative Neoplasms Ruxolitinib

Dr Jean-Jacques Kiladjian discusses the results of the follow up to the RESPONSE study of ruxolitinib versus standard therapy for the treatment of patients with polycythemia vera.

More from Jean-Jacques Kiladjian

1:14
The importance of patient registries
Jean-Jacques Kiladjian • 9 Jun 2016
2:22
Characteristics and outcomes of young patients with MPNs
Jean-Jacques Kiladjian • 16 May 2022
1:15
Drugs under investigation for patients with MF who have failed treatment with JAK inhibitors
Jean-Jacques Kiladjian • 16 May 2022
1:45
What's new in myeloproliferative neoplasms?
Jean-Jacques Kiladjian • 9 Jun 2016

Related Videos

3:03
An insight into the MOMENTUM trial: safety and efficacy of momelotinib for the treatment of MF
Srdan Verstovsek • 22 Jun 2022
3:08
REVEAL: association between elevated blood counts and thrombotic events in polycythemia vera
Aaron Gerds • 15 Jun 2022
3:18
First-line treatment selection in myelofibrosis
Aaron Gerds • 15 Jun 2022
3:48
Efficacy of momelotinib in thrombocytopenic patients with myelofibrosis from MOMENTUM
Aaron Gerds • 15 Jun 2022
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals